A recent study compared the effects of ADSCs from different breast adipose sources (invasive breast cancer, BRCA-mutated invasive breast cancer, ductal carcinoma in situ, healthy controls) on multiple breast cancer cell lines and found that ADSCs from invasive breast cancer patients displayed a significant enhancement on the proliferation and metastasis of JIMT in vivo and in vitro, which was HER2-enriched and anti-HER2 resistant, but exhibited a weak promotion effect on T47D and no effect on MDA231 [99]. Here, ERBB2 is linked to breast cancer.